When compared to those in the RA-change group, the patients who kept their diagnosis ( RA-keep) were more often RF positive (64% vs 21%, p< 0.001) or ACPA positive (59% vs 8%, p< 0.001). Results: Forty-five patients (1.8%) were misdiagnosed ( RA-change group). The groups were analysed with respect to the individual classification criteria, antibodies to citrullinated proteins (ACPA), disease activity (DAS28) and radiographic changes from inclusion up to 2 years. Methods: Patients in the BARFOT (Better Anti-Rheumatic PharmacOTherapy) cohort (n=2543) with at least four follow-up visits during the initial 5 years from enrolment were assessed, and a change in diagnosis was reported by the treating rheumatologist. Here, we examined the differences between actual and misdiagnosed RA cases in a long-term cohort of patients included based on the ACR-1987 classification criteria.
No pathognomonic test is available, and diagnosis is based on classification criteria, which can result in misdiagnosis.
Objective: Correct diagnosis of early rheumatoid arthritis (RA) is essential for optimal treatment choices. Monica Leu Agelii, 1 Ingiäld Hafström, 2 Björn Svensson, 3 Sofia Ajeganova, 4, 5 Kristina Forslind, 3, 5 Maria Andersson, 3, 5 Inger Gjertsson 1ġDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden 2Department of Medicine Huddinge, Division of Gastroenterology and Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden 3Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden 4Department of Clinical Sciences, Rheumatology Division, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium 5Spenshult Research and Development Center, Halmstad, SwedenĬorrespondence: Inger Gjertsson, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Box 480, 40530 Gothenburg, Sweden, Tel +46- 031-342 4692, Email
0 kommentar(er)
